HMPL-523 ( DrugBank: - )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
46	Malignant rheumatoid arthritis	1
63	Idiopathic thrombocytopenic purpura	1

46. Malignant rheumatoid arthritis

---

Clinical trials : 4,356 /  Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02105129 (ClinicalTrials.gov)	May 2014	19/3/2014	A Study of the Safety, Tolerability and Pharmacokinetics of HMPL-523	A Phase I, Randomized, Double Blind, Placebo-controlled, Dose-escalating Study of the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of HMPL-523	Rheumatoid Arthritis (RA)	Drug: HMPL-523;Drug: Placebo	Hutchison Medipharma Limited	NULL	Completed	18 Years	45 Years	Male	118	Phase 1	Australia

63. Idiopathic thrombocytopenic purpura

---

Clinical trials : 391 /  Drugs : 235 - (DrugBank : 50) / Drug target genes : 49 - Drug target pathways : 139

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05029635 (ClinicalTrials.gov)	October 27, 2021	8/8/2021	Phase III Study on HMPL-523 for Treatment of ITP	A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HMPL-523 in Treatment of Primary Immune Thrombocytopenia (ITP) in Adults(ESLIM-01 Study)	Primary Immune Thrombocytopenia (ITP)	Drug: HMPL-523;Drug: Placebo	Hutchison Medipharma Limited	NULL	Active, not recruiting	18 Years	75 Years	All	188	Phase 3	China